Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Another Opinion: Examining the Chronic Pain Landscape and Regulatory Environment- Where does DepoMed's NUCYNTA (tapentadol) fit in?

Ticker(s): DEPO, ENDP

Who's the expert?

Institution: Murphy Pain Center & University of Louisville School of Medicine.

  • Medical Director of Murphy Pain Center, Assistant Clinical Professor at ULSOM, Dr. Murphy is an anesthesiologist and interventional pain specialist who was one of the nation’s first physicians board-certified in both Pain Medicine and Addiction Medicines, after completing his fellowship at the Mayo Clinic.
  • Extensive experience will all aspects of opioid use with 100% of practice dedicated to the treatment of chronic severe pain. ~10 patients on NUCYNTA ER (tapentadol)
  • Worked with regulators in crafting prescription guidelines, contributes to numerous publications and has presented before national and international audiences regarding pain and addiction. 

Interview Questions
Q1.

Please describe your clinical practice. How many patients with chronic pain do you currently treat? With acute pain?

Added By: c_admin
Q2.

What is your experience to date with NUCYNTA (tapentadol)? Do you have patients on both the regular and extended release formulation?

Added By: c_admin
Q3.

Have your patients had problems with reimbursement with regard to this drug? Is the cost of Nucynta a major issue for patients receiving access to the medication, and if yes, what is your alternative plan of action?

Added By: c_admin
Q4.

Given the currently regulatory environment with regard to opioids, how has your prescribing pattern changed over the last several years?

Added By: c_admin
Q5.

What is your preferred, and most often recommended, oral opiod overall for both IR and ER?

Added By: c_admin
Q6.

What other opioids do you and your colleagues favor? Opana? Oxycontin?

Added By: c_admin
Q7.

Do you prescribe Nucynta exclusively as indicated on label or are there benefits of the drug that you are aware of not explicitly mentioned? If yes, are your colleagues aware of said possible benefits also?

Added By: c_admin
Q8.

On a scale of 1 to 10 how powerful of an opiod do you consider Nucynta, and do you feel the label recommended dosages are too low/high?

Added By: c_admin
Q9.

Do you interact with Nucynta sales representatives, and if yes, do they do a satisfactory job of informing you about the benefits of the drug?

Added By: c_admin
Q10.

On a scale of 1 to 10 how would you rate Nucynta overall? What are some flaws and short comings of the drug?

Added By: c_admin
Q11.

Does does the FDA asking for the removal of Opana ER make sense to you as a prescribing physician given it was for abuse related  issues and not efficacy or safety? How do you as a physician balance that with current generic abusable formulations?

Added By: kikiru
Q12.

Also, any insights on what he thinks may happen at FDA on the opana generic side would be helpful.

Added By: joe_mccann
Q13.

What would you put in place with the removal of Opana ER?

Added By: usera1e12dae
Q14.

With the recent negative optics around prescribing opioids, how has your practice changed? Are you seeing more referrals from primary care physicians? Is there a need to expand your practice to accommodate these patients? How would you do this? Nurse practitioners? 

Added By: kikiru
Q15.

Do you participate in any of the Nucynta speaker series and if so are you compensated?

Added By: kikiru
Q16.

Thoughts on Xtampza? – Some big formulary wins of late with United and several Medicare payors - some cases those plans are taking oxy off formulary.

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.